CN102861028B - Gypensapogenin B在预防或治疗胰腺纤维化的药物中的应用 - Google Patents
Gypensapogenin B在预防或治疗胰腺纤维化的药物中的应用 Download PDFInfo
- Publication number
- CN102861028B CN102861028B CN201210417013.XA CN201210417013A CN102861028B CN 102861028 B CN102861028 B CN 102861028B CN 201210417013 A CN201210417013 A CN 201210417013A CN 102861028 B CN102861028 B CN 102861028B
- Authority
- CN
- China
- Prior art keywords
- gypensapogenin
- medicine
- preventing
- pancreatic fibrosis
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- NNUMQZNZQGQGCN-AGHUFMIKSA-N gypensapogenin b Chemical compound O=C1C(=C(C)C)CC([C@@H]2[C@@H]3[C@@]([C@@]4(CCC5=C([C@H]6CC[C@H](O6)C5(C)C)[C@H]4CC3)C)(C)CC2)=C1 NNUMQZNZQGQGCN-AGHUFMIKSA-N 0.000 title claims abstract description 64
- 206010016654 Fibrosis Diseases 0.000 title claims abstract description 24
- 230000004761 fibrosis Effects 0.000 title claims abstract description 24
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 210000004907 gland Anatomy 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 9
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 5
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 5
- 229960002591 hydroxyproline Drugs 0.000 claims description 5
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 5
- GGLZPLKKBSSKCX-UHFFFAOYSA-N S-ethylhomocysteine Chemical compound CCSCCC(N)C(O)=O GGLZPLKKBSSKCX-UHFFFAOYSA-N 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 11
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000000496 pancreas Anatomy 0.000 description 13
- 230000002946 anti-pancreatic effect Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 3
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 235000017709 saponins Nutrition 0.000 description 3
- 150000003648 triterpenes Chemical class 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- INLFWQCRAJUDCR-IQVMEADQSA-N (1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane] Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CCCCC4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 INLFWQCRAJUDCR-IQVMEADQSA-N 0.000 description 1
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- RSBNUWAVVQOBHL-UHFFFAOYSA-N C(CC)O.CC1=C(C(=O)O)C=CC=C1C(=O)O Chemical compound C(CC)O.CC1=C(C(=O)O)C=CC=C1C(=O)O RSBNUWAVVQOBHL-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- OORMXZNMRWBSTK-UHFFFAOYSA-N dammaran Natural products C1CCC(C)(C)C2CCC3(C)C4(C)CCC(C(C)CCCC(C)C)C4CCC3C21C OORMXZNMRWBSTK-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Landscapes
- Steroid Compounds (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210417013.XA CN102861028B (zh) | 2012-10-26 | 2012-10-26 | Gypensapogenin B在预防或治疗胰腺纤维化的药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210417013.XA CN102861028B (zh) | 2012-10-26 | 2012-10-26 | Gypensapogenin B在预防或治疗胰腺纤维化的药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102861028A CN102861028A (zh) | 2013-01-09 |
CN102861028B true CN102861028B (zh) | 2014-04-16 |
Family
ID=47440346
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210417013.XA Active CN102861028B (zh) | 2012-10-26 | 2012-10-26 | Gypensapogenin B在预防或治疗胰腺纤维化的药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102861028B (zh) |
-
2012
- 2012-10-26 CN CN201210417013.XA patent/CN102861028B/zh active Active
Non-Patent Citations (3)
Title |
---|
Li, N. et al..Triterpenes possessing an unprecedented skeleton isolated from hydrolyzate of total saponins from Gynostemma pentaphyllum.《European Journal of Medicinal Chemistry》.2012,第50卷第173-178页. * |
Two new dammaran sapogenins from leaves of Panax notoginseng.;Wei, J.X. et al.;《Planta Medica》;19821231;第45卷(第3期);第167-171页 * |
Wei, J.X. et al..Two new dammaran sapogenins from leaves of Panax notoginseng..《Planta Medica》.1982,第45卷(第3期),第167-171页. |
Also Published As
Publication number | Publication date |
---|---|
CN102861028A (zh) | 2013-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104147019B (zh) | 闭花木酮的o-(四氢吡咯基)乙基衍生物在制备预防或治疗胰腺纤维化药物中的应用 | |
CN102861028B (zh) | Gypensapogenin B在预防或治疗胰腺纤维化的药物中的应用 | |
CN102872054B (zh) | Gypensapogenin A在制备预防或治疗胰腺纤维化的药物中的应用 | |
CN102872126B (zh) | Houttuynoid E在预防或治疗胰腺纤维化的药物中的应用 | |
CN103356580A (zh) | Sarcaboside A在预防胰腺纤维化的药物中的应用 | |
CN102872143B (zh) | Houttuynoid D在预防或治疗胰腺纤维化的药物中的应用 | |
CN105497024A (zh) | Herqueiazole在制备预防或治疗胰腺纤维化药物中的应用 | |
CN103393669B (zh) | Chukrasone B在制备预防胰腺纤维化的药物中的应用 | |
CN103381167B (zh) | Chukrasone A在制备预防胰腺纤维化的药物中的应用 | |
CN102872127B (zh) | Houttuynoid C在预防或治疗胰腺纤维化的药物中的应用 | |
CN102872124B (zh) | Houttuynoid A在预防或治疗胰腺纤维化的药物中的应用 | |
CN103393659A (zh) | Sarcaboside B在预防胰腺纤维化的药物中的应用 | |
CN105395560A (zh) | Astataricusol A在制备预防或治疗胰腺纤维化药物中的应用 | |
CN105326836A (zh) | Alistonitrine A在制备预防或治疗胰腺纤维化药物中的应用 | |
CN103120660A (zh) | Eryngiolide A在预防或治疗胰腺纤维化的药物中的应用 | |
CN105287489A (zh) | Furanocyclocommunin在制备预防或治疗胰腺纤维化药物中的应用 | |
CN103120686A (zh) | Aphanamixoid A在预防或治疗胰腺纤维化的药物中的应用 | |
CN103285005A (zh) | 化合物在制备预防或治疗胰腺纤维化药物中的应用 | |
CN103340875A (zh) | 化合物在制备预防或治疗胰腺纤维化药物中的应用 | |
CN106344565A (zh) | Ternatusine A在制备预防或治疗胰腺纤维化药物中的应用 | |
CN102872120A (zh) | Houttuynoid B在预防或治疗胰腺纤维化的药物中的应用 | |
CN106265689A (zh) | Friedolanostanes在制备预防或治疗胰腺纤维化药物中的应用 | |
CN106344556A (zh) | Fistulains B在预防或治疗胰腺纤维化药物中的应用 | |
CN101032502B (zh) | 积雪苷在制备预防或治疗胰腺纤维化的药物中的应用 | |
CN105232508A (zh) | 一种组合物及其在预防或治疗胰腺纤维化药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: RUDONG TECHNOLOGY CENTER Free format text: FORMER OWNER: NANJING UNIVERSITY Effective date: 20141226 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210093 NANJING, JIANGSU PROVINCE TO: 226400 NANTONG, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20141226 Address after: 226400 No. 66 Youyi West Road, dug Town, Rudong County, Jiangsu, Nantong Patentee after: Rudong science and Technology Center Address before: 210093 Nanjing, Gulou District, Jiangsu, No. 22 Hankou Road Patentee before: Nanjing University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200423 Address after: No. 10, Fandi South Road, juegang Town, Rudong County, Nantong City, Jiangsu Province Patentee after: Rudong industrial and commercial information consulting service center Address before: 226400 No. 66 Youyi West Road, dug Town, Rudong County, Jiangsu, Nantong Patentee before: Rudong science and Technology Center |
|
TR01 | Transfer of patent right |
Effective date of registration: 20211221 Address after: Fengli town Xinjian West Road, Rudong County, Nantong City, Jiangsu Province 226400 Patentee after: Rudong Wenyuan investment and Development Co., Ltd Address before: 226400 No.10 Fandi South Road, juegang Town, Rudong County, Nantong City, Jiangsu Province Patentee before: Rudong industrial and commercial information consulting service center |
|
TR01 | Transfer of patent right |